MRNA Q3 2025 Earnings — Income Statement Breakdown
For its Q3 2025 period (ending 2025-09-30), MRNA reported revenue of $1.0B, gross profit of $809M (79.6% gross margin), operating income of −$260M, and net income of −$200M (-19.7% net margin). The flow of revenue into costs and profit is visualized below.
What changed
MRNA reported a net loss; no comparable cached period is available.
| Comparison | Revenue | Net income | Net margin |
|---|---|---|---|
| Year over year | Not available | Not available | Not available |
| Quarter over quarter | Not available | Not available | Not available |
Consensus estimate data is not available for this report.
MRNA Q3 2025 Income Statement
| Line item | Amount (USD) | % of revenue |
|---|---|---|
| Revenue | $1.0B | 100% |
| Cost of Revenue | −$207M | 20.4% |
| Gross Profit | $809M | 79.6% |
| Research & Development | −$801M | 78.8% |
| Selling, General & Administrative | −$268M | 26.4% |
| Operating Income | −$260M | -25.6% |
| Other Income, net | $73M | 7.2% |
| Income Tax Expense | −$13M | 1.3% |
| Net Income | −$200M | -19.7% |
Source: original SEC filing (filed 2025-11-06). Accession 0001682852-25-000073. Data normalized by EarningsFyi.